Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06832618 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
A Phase 3 study of Atopic Dermatitis, sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
- 20
- Study locations
NCT06832618 is a Phase 3 study of Atopic Dermatitis that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 240 participants, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT06832618, a Phase 3 study of Atopic Dermatitis, is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to assess the efficacy and safety of ruxolitinib cream in children and adolescents (6 to \<18 Years Old) with moderate atopic dermatitis.
Conditions Studied
Interventions
- DRUG Ruxolitinib
- DRUG Vehicle Cream
Study Locations (20)
Georgia
- Lane Dermatology and Dermatologic Surgery - Columbus
- Cleaver Medical Group - Cumming
Illinois
- Sneeze Wheeze and Itch Associates Llc - Normal
- Endeavor Health Medical Group - Skokie
Michigan
- Oakland Hills Dermatology Pc - Auburn Hills
- Henry Ford Health System - Detroit
Missouri
- Red River Research Partners - Bolivar
- Medisearch Clinical Trials - Saint Joseph
Alabama
- Clinical Research Center of Alabama - Birmingham
Arizona
- Saguaro Dermatology - Phoenix
Colorado
- National Jewish Health - Denver
Florida
- Encore Medical Research, Llc Hollywood - Hollywood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2025-06-17 |
| Est. Completion | 2028-05-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06832618
The ClinicalTrials.gov registry entry for NCT06832618 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (61% lower). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Ruxolitinib is the first listed.
NCT06832618 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Georgia, Illinois, Michigan.
Frequently Asked Questions
What is clinical trial NCT06832618 about?
NCT06832618 is a clinical study titled "A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis". The purpose of the study is to assess the efficacy and safety of ruxolitinib cream in children and adolescents (6 to \<18 Years Old) with moderate atopic dermatitis.
What is the current status of trial NCT06832618?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2025-06-17. Estimated completion is 2028-05-18.
What conditions does trial NCT06832618 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT06832618?
The interventions under investigation include: Ruxolitinib (DRUG), Vehicle Cream (DRUG).
Who is sponsoring clinical trial NCT06832618?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06832618 being conducted?
This trial has 20 study locations across Alabama, Arizona, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
RECRUITING · Phase 3
-
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
RECRUITING · Phase 3
-
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
RECRUITING · Phase 3
-
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.